Casper Steenholdt

Dr. Casper Steenholdt

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2023 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
CSCasper Steenholdt
Casper Steenholdt
POPernille Dige Ovesen
Pernille Dige Ovesen
JBJørn Brynskov
Jørn Brynskov
JSJakob Benedict Seidelin
Jakob Benedict Seidelin
Tofacitinib has emerged as a new potential treatment for acute severe ulcerative colitis [ASUC]. We conducted a systematic review to assess efficacy, safety and integration in ASUC algorithms. Systematic searching was done in MEDLINE, EMBASE, Cochrane Library and Clinicaltrials.gov until August 17, 2022, including all studies reporting original observations on tofacitinib for ASUC, preferably defined according to Truelove and Witts criteria. The primary outcome was colectomy-free survival. Of 1072 publications identified, 21 studies were included of which three were ongoing clinical trials. The remaining comprised a pooled cohort originating from 15 case publications [n = 42], a GETAID cohort study [n = 55], a case-control study [n = 40 cases] and a paediatric cohort [n = 11]. Of these 148 reported cases, tofacitinib was used as second-line treatment after steroid failure in previous infliximab failures or third-line after sequential steroid and infliximab or cyclosporine failure, 69 [47%] were female, median age range was 17–34 years and disease duration was 0.7–10 years. Overall, 30-day colectomy-free survival was 85% [n = 123 of 145; n = 3 without colectomy had follow-up <30 days], 90-day 86% [n = 113 of 132; n = 16 follow-up <90 days] and 180-day 69% [n = 77 of 112; n = 36 follow-up <180 days]. Tofacitinib persistence at follow-up was 68–91%, clinical remission 35–69% and endoscopic remission 55%. Adverse events occurred in 22 patients, predominantly being infectious complications other than herpes zoster [n = 13], and resulted in tofacitinib discontinuation in seven patients. Tofacitinib appears promising for treatment of ASUC with high short-term colectomy-free survival among refractory patients who are otherwise deemed to require colectomy. However, large high-quality studies are needed.

16 October 2017 in BMC Medicine
Verified
Journal Article
Open access
PDF file
Jacob Tveiten BjerrumJacob Tveiten Bjerrum
Jacob Tveiten Bjerrum
CSCasper Steenholdt
Casper Steenholdt
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth
Ole Haagen NielsenOle Haagen Nielsen
Ole Haagen Nielsen
MRMichelle Ac Reed
Michelle Ac Reed
YWYulan Wang
Yulan Wang
One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance. This study employs spectroscopy-based metabolic profiling of serum from patients with IBD treated with IFX and healthy subjects (1) to substantiate the use of spectroscopy as a semi-invasive diagnostic tool, (2) to identify potential biomarkers of treatment response and (3) to characterise the metabolic changes during management of patients with tumour necrosis factor-α inhibitors. Successive serum samples collected during IFX induction treatment (weeks 0, 2, 6 and 14) from 87 IBD patients and 37 controls were analysed by 1H nuclear magnetic resonance (NMR) spectroscopy. Data were analysed with principal components analysis and orthogonal projection to latent structures discriminant analysis using SIMCA-P+ v12 and MATLAB. Metabolic profiles were significantly different between active ulcerative colitis and controls, active Crohn’s disease and controls, and quiescent Crohn’s disease and controls. Metabolites holding differential power belonged primarily to lipids and phospholipids with proatherogenic characteristics and metabolites in the pyruvate metabolism, suggestive of an intense inflammation-driven energy demand. IBD patients not responding to IFX were identified as a potentially distinct group based on their metabolic profile, although no applicable response biomarkers could be singled out in the current setting. 1H NMR spectroscopy of serum samples is a powerful semi-invasive diagnostic tool in flaring IBD. With its use, we provide unique insights into the metabolic changes taking place during induction treatment with IFX. Of distinct clinical relevance is the identification of a reversible proatherogenic lipid profile in IBD patients with active disease, which partially explains the increased risk of cardiovascular disease associated with IBD.

13 October 2016 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
HEHelena Edlund
Helena Edlund
CSCasper Steenholdt
Casper Steenholdt
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth
EGEva Goebgen
Eva Goebgen
JBJørn Brynskov
Jørn Brynskov
CKCharlotte Kloft
Charlotte Kloft

1 March 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
CSCasper Steenholdt
Casper Steenholdt
JJJeppe T. Jensen
Jeppe T. Jensen
JBJørn Brynskov
Jørn Brynskov
AMAnn Merete Møller
Ann Merete Møller
ALAnne Christine Limschou
Anne Christine Limschou
PVPeter Vilmann
Peter Vilmann

5 February 2024 in Trends in Molecular Medicine
Verified
Journal Article
Open access
AHAnnika Hausmann
Annika Hausmann
CSCasper Steenholdt
Casper Steenholdt
Ole Haagen NielsenOle Haagen Nielsen
Ole Haagen Nielsen
KJKim B. Jensen
Kim B. Jensen
The intestinal epithelium fulfills important physiological functions and forms a physical barrier to the intestinal lumen. Barrier function is regulated by several pathways, and its impairment contributes to the pathogenesis of inflammatory bowel disease (IBD), a chronic inflammatory condition affecting more than seven million people worldwide. Current treatment options specifically target inflammatory mediators and have led to improvement of clinical outcomes; however, a significant proportion of patients experience treatment failure. Pro-repair effects of inflammatory mediators on the epithelium are emerging. In this review we summarize current knowledge on involved epithelial pathways, identify open questions, and put recent findings into clinical perspective, and pro-repair effects. A detailed understanding of epithelial pathways integrating mucosal stimuli in homeostasis and inflammation is crucial for the development of novel, more targeted therapies.

14 November 2017 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
DMDitte V Mogensen
Ditte V Mogensen
JBJørn Brynskov
Jørn Brynskov
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth
JNJacob Nersting
Jacob Nersting
KSKjeld Schmiegelow
Kjeld Schmiegelow
CSCasper Steenholdt
Casper Steenholdt
Interactions between principal cytotoxic thiopurine metabolites, that is 6-thioguanine nucleotides [6-TGN], and infliximab [IFX] and anti-IFX antibodies [Abs] may contribute to higher effectiveness of IFX-thiopurine combination therapy than monotherapies in inflammatory bowel disease. To examine if thiopurine metabolites influenced trough IFX and anti-IFX Abs, 89 patients previously assessed for anti-IFX Abs were included. To assess if IFX influenced thiopurine metabolites, eight patients who had responded to 12 weeks of intensified IFX at a constant thiopurine dosing were included. In the first cohort, IFX-thiopurine combination therapy reduced anti-IFX Ab detection [8/40; 20%] as compared with IFX monotherapy [22/49; 45%], odds ratio [OR] 0.31 [0.12–0.80], p < 0.05. 6-TGN was significantly lower in anti-IFX Ab-positive patients (50 pmol/8 × 108 red blood cells [RBC] vs 105, p < 0.01). All anti-IFX Ab-positive patients had 6-TGN < 117 pmol/8 × 108 RBC (sensitivity 100% [63–100], specificity 47% [29–65], area under the curveROC = 0.82, p < 0.01). Trough IFX was similar between anti-IFX Ab-negative patients in IFX monotherapy and IFX-thiopurine combination therapy [5.1 μg/mL vs 4.9, p = 0.76]. 6-TGN and IFX did not correlate [rP = 0.04, p = 0.83; rS = 0.02, p = 0.89, respectively]. In the second cohort, trough IFX increased during IFX intensification [ΔIFX median 6.5 μg/mL, p = 0.02], but 6-TGN was stable [6-TGN at Weeks 0, 4, 8, 12: 90 pmol/8 × 108 RBC, 93, 101, 90; p > 0.05]. Methylated mercaptopurine metabolite associations were consistently negative. Superior effect of IFX-thiopurine combination therapy over monotherapies partly relates to decrease in anti-IFX Abs, which associates with 6-TGN levels and has a lower therapeutic threshold than during thiopurine monotherapy. Additional benefit likely ascribes to synergy between different anti-inflammatory modes of action rather than direct drug interactions.